Spinal cord injuries (SCI) are the injuries caused to the thirty one pairs of spinal nerves, which carry nerve signals from brain to various parts of the body and also controls the arm and leg movements. The main cause of spinal cord injuries include trauma, loss of blood supply to spinal cord, and compression in spinal cord due to tumor or infections. Spinal cord injuries can be diagnosed with the help of various techniques such as X-ray, magnetic resonance index (MRI), and computed tomography (CT).
This report contains market size and forecasts of Spinal Cord Injury Therapeutic in global, including the following market information:
Global Spinal Cord Injury Therapeutic Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Spinal Cord Injury Therapeutic Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Spinal Cord Injury Therapeutic companies in 2021 (%)
The global Spinal Cord Injury Therapeutic market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Oral Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Spinal Cord Injury Therapeutic include Teva Pharmaceutical Industries Ltd., AbbVie Inc., Pfizer Inc., Dr. Reddy's Laboratories Ltd., Zydus Cadila, ReNetX Bio, Inc., InVivo Therapeutics Holdings, Lineage Cell Therapeutics Inc. and Kringle Pharma, Inc., etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Spinal Cord Injury Therapeutic manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Spinal Cord Injury Therapeutic Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Spinal Cord Injury Therapeutic Market Segment Percentages, by Type, 2021 (%)
Oral
Intravenously
Global Spinal Cord Injury Therapeutic Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Spinal Cord Injury Therapeutic Market Segment Percentages, by Application, 2021 (%)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Spinal Cord Injury Therapeutic Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Spinal Cord Injury Therapeutic Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Spinal Cord Injury Therapeutic revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Spinal Cord Injury Therapeutic revenues share in global market, 2021 (%)
Key companies Spinal Cord Injury Therapeutic sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Spinal Cord Injury Therapeutic sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Teva Pharmaceutical Industries Ltd.
AbbVie Inc.
Pfizer Inc.
Dr. Reddy's Laboratories Ltd.
Zydus Cadila
ReNetX Bio, Inc.
InVivo Therapeutics Holdings
Lineage Cell Therapeutics Inc.
Kringle Pharma, Inc.
Acorda Therapeutics, Inc.
Bioaxone Biosciences, Inc.
RespireRx Pharmaceuticals Inc.
NervGen
Rising Pharmaceuticals, Inc.
ScieGen Pharmaceuticals, Inc.
MSN Laboratories Private Limited
Lannett Co Inc.